Loading viewer...
investor_presentation
Format: PDF investor_presentation
Full Year 2019 results February 26, 2020 February 26th, 2020 Full Year 2019 Results 1
February 26th, 2020 Full Year 2019 Results 1Webcast
2 February 26th, 2020 Full Year 2019 ResultsIFRS 16hasbeen implemented intheGroup’s financial statements since January 1,2019.Comparative information forthefirstquarter of
2018 inthebusiness review ispresented onanunaudited proforma basis asiftheimplementation hadtaken place onJanuary 1,2018.This
information islabelled “proforma” or“PF”.Thebalance sheet evolution iscompared withJanuary 1,2019,which includes theIFRS 16impact
versus December 31,2018.
Besides IFRS accounts, Solvay also presents underlying Income Statement performance indicators toprovide amore consistent and
comparable indication oftheGroup’s financial performance .Theunderlying performance indicators adjust IFRS figures forthenon-cash
Purchase Price Allocation (PPA) accounting impacts related toacquisitions, forthecoupons ofperpetual hybrid bonds, classified asequity
under IFRS buttreated asdebtintheunderlying statements, andforother elements thatwould distort theanalysis oftheGroup’s underlying
Thispresentation maycontain forward -looking information .Forward -looking statements describe expectations, plans, strategies, goals, future
events orintentions .Theachievement offorward -looking statements contained inthispresentation issubject torisks anduncertainties
relating toanumber offactors, including general economic factors, interest rateandforeign currency exchange ratefluctuations, changing
market conditions, product competition, thenature ofproduct development, impact ofacquisitions anddivestitures, restructurings, products
withdrawals, regulatory approval processes, all-inscenario ofR&Dprojects andother unusual items .
Consequently, actual results orfuture events may differ materially from those expressed orimplied bysuch forward -looking statements .
Should known orunknown risks oruncertainties materialize, orshould ourassumptions prove inaccurate, actual results could varymaterially
from those anticipated .TheCompany undertakes noobligation topublicly update orrevise anyforward -looking statements .
Thisdocument does notconstitute anoffer tosell,orthesolicitation ofanoffer tosubscribe fororbuy,anysecurities .Forenote
February 26th, 2020 Full Year 2019 Results 3Focus on cost, cash and customers in a challenging macro environment2019 Financial results
EBITDAFYFREE CASH FLOW
toSolvay Shareholders
from continuing operations
Price partly offsets volumesForeign exchange
offsets 2.8% decreaseDisciplined focus
delivers solid results
Q4: €2,440 m Q4: €525 m Q4: €261 m€10 bn€2.3 bn€606 m
February 26th, 2020 Full Year 2019 Results 4Strategic update
February 26th, 2020 Full Year 2019 Results 5Portfolio
•Divestment of Polyamides
•Net Proceeds of €1.2 billion
Preview truncated — download the full document for the complete content.
earnings
28 Pages
investor_presentation
50 Pages
Altium
investor_presentation
Kazia Therapeutics